CDCP1 and acute myeloid leukemia: To confirm these results in patients receiving anthracycline-based induction therapy, multivariate analysis including age (< 60 vs. ≥ 60 years), WBC, primary/secondary AML, risk profile according NCCN, and CD318 expression was conducted.